Quidel Corporation
318 articles about Quidel Corporation
-
Quidel Announces Preliminary Revenue for Fiscal Third Quarter 2021
10/7/2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today preliminary results for the third quarter of 2021.
-
Quidel Reports Second Quarter 2021 Financial Results
8/5/2021
Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced financial results for the second quarter ended June 30, 2021.
-
Quidel Announces Agreement With Beckman Coulter That Terminates Ongoing Litigation and Transitions BNP Business to Beckman Coulter
7/26/2021
Settlement Agreement ends litigation that began in November 2017, following Quidel’s acquisition of the BNP Business from Alere, Inc. (“Alere”). Quidel to receive cash payments between $70 million to $75 million per year through 2029
-
State of Delaware Selects Quidel for COVID-19 Testing Program at Schools
7/19/2021
Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.
-
Quidel to Hold Fiscal Second Quarter 2021 Financial Results Conference Call on August 5th, 2021
7/14/2021
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal second quarter 2021 financial results after market close on Thursday, August 5, 2021.
-
Quidel Receives CE Mark for Savanna® Multiplex Molecular Analyzer and Respiratory Viral Panel
7/12/2021
Quidel Corporation announced today that the company has received the CE Mark for its innovative Savanna® multiplex molecular analyzer and Savanna® RVP4 Assay (Respiratory Viral Panel-4).
-
With Lyme Disease on the Rise Nationwide, Quidel Corporation Urges Early Testing With Its Rapid Point-of-Care Test
6/24/2021
As America approaches the tail end of the COVID-19 pandemic, a quiet epidemic has emerged that has the potential to affect as many as 476,000 citizens before the year is out.
-
Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device
6/11/2021
Quidel Receives Amended Emergency Use Authorization for New Sofia ® Q Rapid Antigen Test Device
-
Quidel to Present Virtually at Raymond James Human Health Innovation Conference 2021
6/10/2021
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James Human Health Innovation Conference 2021 to be held virtually on Monday, June 21, 2021.
-
Health Canada Approves Quidel’s Sofia® SARS Antigen FIA Test for Screening of Asymptomatic Populations With Serial Testing
5/24/2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”) , a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active coronavirus infection in both symptomatic and asymptomatic populations.
-
Quidel’s QuickVue® At-Home OTC COVID-19 Test Now Available for Sale Through Amazon
5/14/2021
Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that its non-prescription QuickVue® At-Home OTC COVID-19 Test is now available in the United States to consumers for online order through e-commerce retailer Amazon.
-
Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests
5/6/2021
Agreement will make QuickVue® At-Home rapid antigen tests available without a prescription at 7,600 Walgreens locations nationwide and online at walgreens.com
-
Quidel Reports First Quarter 2021 Financial Results
5/6/2021
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2021.
-
Quidel to Present Virtually at the BofA Securities 2021 Health Care Conference
5/4/2021
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the BofA Securities 2021 Health Care Conference
-
Teaching Doctors Nationwide How to Recognize and Differentiate Between Lyme Disease, COVID-19 and the Flu in Quidel-Hosted May 5 Webinar
4/27/2021
With Lyme disease season emerging and the COVID-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5.
-
Quidel to Hold Fiscal First Quarter 2021 Financial Results Conference Call on May 6th, 2021
4/26/2021
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2021 financial results after market close on Thursday, May 6, 2021.
-
Quidel Signs Retail Distribution Agreement to Increase Access to At-Home COVID-19 Testing
4/22/2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”) , a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has completed a distribution and fulfillment agreement with McKesson Corporation
-
Quidel Announces Preliminary Revenue for First Quarter 2021
4/22/2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today preliminary results for the first quarter of 2021. The Company expects revenues in the first quarter of 2021 to be in the range of $374 million
-
Quidel Corporation Partners With the Bay Area Lyme Foundation to Heighten Public Awareness of Lyme Disease
4/13/2021
With Lyme disease season breaking out across the United States, Quidel Corporation announced today that it has partnered with the Bay Area Lyme (BAL) Foundation to help heighten public awareness to this alarming health condition that afflicts as many as 400,000 Americans each year. Quidel is the nation’s leading developer of rapid Lyme disease testing.
-
Start of Lyme Disease Season Provides Heightened Risks for Americans Wanting to Go Outdoors After a Year of COVID-19 Restrictions
4/5/2021
Quidel Corporation, the Nation’s Leading Developer of Rapid Lyme Disease Testing, Cautions Americans to be Vigilant, Take Precautions and Get Tested if in Doubt